Breast Cancer Gene Case Has Another Day in Court
By Eric Hoffman and Jaydee Hanson, Biopolitical Times guest contributors
| 04. 07. 2011
A three-judge federal appeals court heard arguments on Monday in a
case that could decide the future of human gene patents. The
high-profile lawsuit was filed by the American Civil Liberties Union and
the Public Patent Foundation on behalf of a number of researchers,
patients, women’s health organizations and scientific organizations
against Myriad Genetics and the University of Utah Research Foundation,
holders of patents on genes known as BRCA1 and BRCA2 that are associated
with elevated risk of breast cancer. The plaintiffs argue that the US
Patent and Trade Office erred in granting these patents because genes
are products of nature, not human inventions.
The panel heard Myriad’s appeal of a decision strongly favoring the
plaintiffs that was issued in March 2010 by Federal District Court Judge
Robert Sweet. Whatever is decided by the appeals court, many observers
expect the case to continue on to the Supreme Court.
A few things stood out in Monday’s hearing. First, the judges were very
interested in whether all the plaintiffs actually have standing in the
case – that is, in whether they have...
Related Articles
By Katie Hunt, CNN | 07.30.2025
Scientists are exploring ways to mimic the origins of human life without two fundamental components: sperm and egg.
They are coaxing clusters of stem cells – programmable cells that can transform into many different specialized cell types – to form...
By Ewen Callaway, Nature | 08.04.2025
For months, researchers in a laboratory in Dallas, Texas, worked in secrecy, culturing grey-wolf blood cells and altering the DNA within. The scientists then plucked nuclei from these gene-edited cells and injected them into egg cells from a domestic dog ...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...